CAMBRIDGE, Mass., Oct. 6, 2021 /PRNewswire/ -- Theseus
Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company
focused on improving the lives of cancer patients through the
discovery, development and commercialization of transformative
targeted therapies, today announced the pricing of its initial
public offering of 10,000,200 shares of its common stock at a price
to the public of $16.00 per share.
All of the shares are being offered by Theseus. The gross proceeds
to Theseus from the offering, before deducting underwriting
discounts, commissions and other offering expenses payable by
Theseus, are expected to be $160
million. In addition, Theseus has granted the underwriters a
30-day option to purchase up to an additional 1,500,030 shares of
common stock from Theseus at the initial public offering price less
underwriting discounts and commissions.
Theseus's common stock is expected to begin trading on The
Nasdaq Global Select Market under the ticker symbol "THRX"
on October 7, 2021. The offering is expected to close on or
about October 12, 2021, subject to the satisfaction of
customary closing conditions.
Jefferies, SVB Leerink and Cantor are acting as joint
book-running managers for the offering. Wedbush PacGrow is acting
as lead manager.
A registration statement relating to the securities being sold
in the offering was declared effective by the Securities and
Exchange Commission ("SEC") on October 6, 2021. The offering
is being made only by means of a written prospectus. Copies of
these documents can be accessed by visiting the SEC website at
http://www.sec.gov. Alternatively, copies of the final prospectus
relating to the offering can be obtained, when available, from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York,
NY 10022, by telephone at (877) 821-7388, or by email at
prospectus_department@Jefferies.com; SVB Leerink LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800)
808-7525, ext. 6105, or by email at firstname.lastname@example.org;
Cantor Fitzgerald & Co., Attention Capital Markets, 499 Park
Avenue, 4th Floor, New York, NY
10022, or by e-mail at email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Theseus Pharmaceuticals, Inc.
Theseus is a
biopharmaceutical company focused on improving the lives of cancer
patients through the discovery, development and commercialization
of transformative targeted therapies. Theseus is developing
next-generation tyrosine kinase inhibitors (TKIs): "pan-variant"
targeted therapies that address all
major drug resistance mutations. Theseus' lead
product candidate, THE-630, is a pan-variant KIT inhibitor for the
treatment of patients with advanced gastrointestinal stromal tumors
(GIST), whose cancer has developed resistance to earlier lines of
kinase inhibitor therapy. Theseus is also developing a
fourth-generation, selective epidermal growth factor receptor
(EGFR) inhibitor for C797S-mediated resistance to first- or
later-line osimertinib treatment in patients with non-small cell
lung cancer (NSCLC).
View original content to download
SOURCE Theseus Pharmaceuticals